打开APP

新拐点?2014年生物医药裁员数量现下滑20%

  1. 拐点
  2. 生物医药
  3. 裁员

来源:生物谷 2015-01-25 19:15

俗话说得好,没有消息就是最好的消息。2015年或许生物医药工作市场或将迎来一个新拐点。

2015年1月25日讯 /生物谷BIOON/ --近年来,受困于研发成本增大等因素,各大生物医药公司都纷纷对其研发部门进行重组裁员。这也造成了最近几年生物医药企业研发部门裁员人数大大增加的情况。不过,俗话说得好,没有消息就是最好的消息。2015年或许生物医药工作市场或将迎来一个新拐点。

根据美国Challenger, Gray & Christmas公司发布的生物医药产业裁员统计报告显示,在刚刚过去的2014年中,生物医药产业共计宣布裁员17636人,这一数字相较于2013年的22161降低了约20%。2014年生物医药产业裁员人数下滑主要得益于新型生物医药公司的扩大和大型生物医药公司裁员规模缩小。但是,这并不是说过去的一年生物医药公司没有进行大规模裁员计划。例如安进公司此前就宣布了3500-4000人的裁员计划,Allergan公司在未来五年内也将先后裁员1500人,而另一个制药巨头阿斯利康公司也宣布将在2016年前裁减550个工作岗位。

Challenger, Gray & Christmas公司CEO John A. Challenger介绍说,此次裁员人数的缩减表明生物医药产业已经开始从2007年-2009年的大萧条中恢复过来。另一方面,这也和一些生物医药巨头对本公司的研发部门重组完成有关。Challenger同时预测,鉴于美国经济的复苏以及欧美、日本等市场老龄化趋势的进程,人们对药物的需求已经越来越高,这些或都将刺激生物医药企业迎来又一个黄金发展时期。

2015年伊始,一些生物医药公司都已经纷纷开始自己的裁员或扩招计划。去年Illumina 公司与福斯特市签订了一项长达15年的租赁协议,在该市建立了一个36万平方英尺的办公中心。根据规划,Illumina 公司在湾区一半的员工将转移到这里。而这一协议预计将为福斯特市带来源源不断的工作岗位。投桃报李,福斯特市将会在未来对ILLUMINA公司的租赁费用实施优惠政策,这一金额预计将在300-350万美元之间。刚刚被罗氏公司以83亿美元收购的InterMune公司则表示将削减170个工作岗位,占到了公司员工总数的三分之一。而在今年大放异彩的mRNA疗法研发公司Moderna Therapeutics则表示公司将会扩大规模,预计2015年将增加100个工作岗位。(生物谷Bioon.com)

详细英文报道:

" They say no news is good news, but the same might also apply to less bad news than last year, at least where biopharma jobs are concerned.

The industry finished 2014 with a total 17,636 announced jobs cuts-down 20% from 22,161 in 2013, according to the December Job Cut Report of Challenger, Gray & Christmas.

The slide reflected job growth among biotechs driven by new product launches, and less cost-cutting by big biopharma. Not to say there weren't big layoffs: Amgen will chop 3,500 to 4,000 positions by the end of 2015. Allergan said its planned $66 billion acquisition by Actavis won't change earlier plans to lay off about 1,500 employees over five years. And AstraZeneca slated another 550 jobs for elimination by 2016.

The drop also reflected the biopharma industry stabilizing after the sluggish recovery that followed the 2007-09 recession, which was more than offset by disruptions. These ranged from consolidation and layoffs by pharma giants, to the overhauls of the nation's patent laws and healthcare system, John A. Challenger, CEO of Challenger, Gray & Christmas, told GEN.

"Those forces were so strong that they outweighed some of the economic conditions. It does seem like this past year, a large portion of that restructuring that occurred in big pharma had been completed, so that there was less pressure to do that. I do think the pressure relented some," Challenger said. "Generally, the economy is strong. Biotechs are growing. Healthy sectors like pharma have lots of small companies. They're not just dominated by big old-line companies. So by definition, it's a healthy sector because of all that new growth that keeps on occurring, and all the venture money that has been flowing into healthcare."

Biopharmas can be expected to continue picking up the pace of hiring in 2015, Challenger added, as the U.S. economy picks up steam, more new products reach the market, and demand for drugs grows due to aging populations in the U.S., Western Europe, and Japan: "2015 should be relatively benign in terms of layoffs and relatively strong in terms of job growth."

" ILLUMINA: 250 Moving to Foster City

Illumina will move about half its San Francisco Bay Area workforce to its future site in Foster City, CA. The sequencing giant signed a 15-year lease for 360,000 square feet of build-to-suit space for offices, labs, manufacturing, amenities, and parking at the roughly 20-acre Lincoln Centre campus, owner BioMed Realty Trust said.

"In the initial phases, we'll be looking at relocating about 250 employees from different existing facilities in the region, and roughly 100 of those would be manufacturing employees," Chuck Pappalardo, senior director of global facilities and real estate, told the City Council on Tuesday, according to a video of the meeting. "We're currently looking to have the first 200,000 square feet of that 360,000 in or around mid-2017, with the additional 160,000 square feet in mid-2018."

Illumina employs about 500 people in the Bay Area, Paul Bianchi, Illumina's svp-human resources, told the council-part of a global workforce of about 4,000 employees and hundreds of contingent workers. That's nearly double the workforce of 2,200 in September 2012, when he joined the company: "If there is a key word here, it's about growth."

The company will shift to Foster City operations now in Hayward, Redwood City, and Santa Clara-while retaining a fourth Bay Area site at San Francisco's Mission Bay campus. There, Illumina operates an R&D facility and last year launched its Illumina Accelerator Program, which selected its first companies in October.

Illumina has an option for another 160,000 square feet at Lincoln Centre.

In return for the new jobs, Foster City officials plan to reimburse Illumina for fees "in connection with processing and approval of entitlements and permits for development and construction of the project."

"The total amount is estimated to be between $3 million and $3.5 million," City Manager James C. Hardy wrote to the council, based on a projection by city staff. Illumina would be reimbursed the approximately $700,000 per year in sales and use taxes it estimates will be paid to the city by virtue of Illumina being in Foster City.

"Assuming the Incentive Payment Cap was $3.5 million and the Incentive Payments were $700,000 per year, it would take five years for Illumina to be fully reimbursed," Hardy added.

The tax break is part of an Economic Development Incentive Agreement set to be formalized by June 30. Earlier this week, the council unanimously approved a resolution to write the agreement.

" INTERMUNE: 170 Jobs Eliminated

A day after revealing plans to acquire InterMune for $8.3 billion, Roche downplayed the possibility of cost-cutting: "This is not about cost synergies at all. This is a growth story," Roche CEO Severin Schwan told Forbes, pledging to keep InterMune's workforce as intact as possible.

A recent filing with California's Economic Development Department (EDD) tells the rest of the story.

In a Worker Adjustment and Retraining Notification (WARN) Act notice dated December 10, 2014, and received by EDD on December 19, InterMune disclosed plans to eliminate 170 positions effective February 15 at the Brisbane, CA, site that was its headquarters. That would be more than one-third (38%) of InterMune's approximately 450 employees on August 24, 2014, when Roche said it was acquiring the company-and nearly all the approximately 200 InterMune staffers based in Brisbane, just 3 miles north of the South San Francisco offices of another Roche subsidiary, Genentech.

"Roles in several functions that have been found to be duplicative with Genentech's roles have been eliminated," Genentech spokesman Terence Hurley told GEN. "Internal teams at Genentech have been working to map U.S. InterMune employees into similar positions at Genentech whenever possible. However, in many cases, if a position is not deemed comparable, we have opted to eliminate the position, which provides for a comprehensive severance package to those impacted.

According to an August 25, 2014, presentation made to InterMune staffers, "ALL (emphasis in original) InterMune employees are guaranteed their comparable aggregate target compensation and benefits through the end of 2015." Roche also told the employees it would pay out this year the bonuses they earned in 2014.

For those wishing to continue with Genentech, Hurley said, the company is providing opportunities to apply for suitable positions: "The long-term plan is for home office InterMune employees to move to Genentech's South San Francisco offices due to the close proximity of InterMune to Genentech."

Roche has cited the benefit of adding InterMune's idiopathic pulmonary fibrosis (IPF) treatment Esbriet (pirfenidone), which won FDA approval last year and European approval in 2011, to its respiratory portfolio. "Given the expertise and experience of InterMune employees in IPF, we are working to integrate InterMune positions into Roche (outside of the U.S.) and Genentech (within the U.S.) whenever possible," Hurley added.

" MODERNA: About 100 Hires this Year

Moderna Therapeutics has begun to deliver on its promise, announced earlier this month, to nearly double its workforce "in the coming months."

The developer of treatments based on its modified messenger-RNA (mRNA) technology disclosed plans January 5 to expand its workforce of 145 employees with "more than 100 industry leaders, drug development experts, and scientists."

"We anticipate hiring about 100 employees in 2015," Moderna Therapeutics CFO Lorence Kim, M.D., told GEN. "We are hiring across the company in a number of different areas-science, engineering, drug development."

The hiring effort, Dr. Kim said, will include identifying and recruiting industry experts to lead new venture companies focused on specialty treatment areas. Moderna has already launched two such venture companies-Onkaido, which is centered on oncology drug development; and Valera, which specializes in infectious diseases.

The venture companies will be Moderna's vehicles for achieving its ambitious goal of advancing 100 new drugs to clinical trials over the next decade.

"Recruiting top scientists and drug development experts is key to meeting our goals of moving multiple treatments and vaccines to the clinic across multiple modalities and therapeutic areas as quickly as possible," Dr. Kim said.

Those new Moderna staffers can be accommodated in the company's two existing locations in Cambridge, MA, totaling 100,000 square feet. One is in the city's Kendall Square section, which has emerged as a mecca for biopharma employers, while the other is at 320 Bent Street, a site the company expanded into last June 2014.

"We will think strategically about additional space needs as we consider our growth in 2015 and beyond," Dr. Kim said.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->